Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis

Author(s): Laura F. Michael, Veena Rao, Patrick McCollam, Mark C. Kowala, John Wetterau

Journal Name: Current Pharmaceutical Biotechnology

Volume 12 , Issue 9 , 2011

Become EABM
Become Reviewer

Abstract:

Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.

Keywords: Metabolic syndrome, hemostatis, thrombosis, coagulation, cardiovascular disease, diabetes, cardio-metabolic abnormalities, metabolic syndrome patients, thromboembolic events, cardiovascular risk, coronary atheroma progression, Elevated triglyceride-rich VLDL, adipocyte dysfunction, coronary heart disease (CHD)

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 9
Year: 2011
Page: [1463 - 1480]
Pages: 18
DOI: 10.2174/138920111798281081
Price: $65

Article Metrics

PDF: 12